U
KPTI icon

UBS’s Karyopharm Therapeutics KPTI Stock Holding History

UBS’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$558K Buy
+1,064
New +$600K ﹤0.01% 4150

Other funds holding KPTI

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS's KPTI Position: Q3 2014 in Review

UBS opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2014: 1,064 shares worth $558K. The stake represents ﹤0.01% of the portfolio and ranks #4150 among its holdings.

70 funds tracked by Wall St. Rank hold KPTI as of Q3 2014.

  • UBS held 1,064 shares of Karyopharm Therapeutics worth $558K as of Q3 2014.
  • Karyopharm Therapeutics was a new UBS position in Q3 2014.
  • Karyopharm Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4150 holding.
  • 70 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.